Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYPLA1 | O75608 | 1/20 | 0.77 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.77 |
| ▸ | LTA4H | P09960 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12266301 | 0.87 | LYPLA1 (1.00) | LYPLA1LYPLA2LTA4H | |
| SCHEMBL13383487 | 0.84 | LYPLA1 (0.55) | LYPLA1LYPLA2HRH3KEAP1NFE2L2 | |
| SCHEMBL12270908 | 0.84 | LYPLA1 (0.78) | LYPLA1LYPLA2LTA4H | |
| SCHEMBL12270830 | 0.82 | LYPLA1 (0.76) | LYPLA1LYPLA2LTA4HHRH3 | |
| SCHEMBL12270616 | 0.81 | LYPLA1 (0.73) | LYPLA1LYPLA2LTA4HMCHR1HRH3 | |
| SCHEMBL12266251 | 0.81 | CYP1A2 (0.67) | LYPLA1LYPLA2LTA4HEPHX2 | |
| SCHEMBL12266297 | 0.81 | LYPLA1 (0.65) | LYPLA1LYPLA2LTA4HHRH3KEAP1 | |
| SCHEMBL12266342 | 0.81 | LYPLA1 (0.50) | LYPLA1LYPLA2LTA4HEPHX2 | |
| SCHEMBL12271226 | 0.80 | LYPLA1 (0.51) | LYPLA1LYPLA2 | |
| SCHEMBL12270360 | 0.80 | LYPLA1 (0.51) | LYPLA1LYPLA2LTA4HHRH3KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LYPLA1 1153/4885LYPLA2 1988/4885LTA4H 4297/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | LYPLA1 4548/4885LYPLA2 4342/4885LTA4H 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.